57 research outputs found
Association of APOE polymorphism with chronic kidney disease in a nationally representative sample: a Third National Health and Nutrition Examination Survey (NHANES III) Genetic Study
<p>Abstract</p> <p>Background</p> <p>Apolipoprotein E polymorphisms (<it>APOE</it>) have been associated with lowered glomerular filtration rate (GFR) and chronic kidney disease (CKD) with e2 allele conferring risk and e4 providing protection. However, few data are available in non-European ethnic groups or in a population-based cohort.</p> <p>Methods</p> <p>The authors analyzed 5,583 individuals from the Third National Health and Nutrition Examination Survey (NHANES III) to determine association with estimated GFR by the Modification of Diet in Renal Disease (MDRD) equation and low-GFR cases. Low-GFR cases were defined as GFR <75 ml/min/1.73 m<sup>2</sup>; additionally, GFR was analyzed continuously.</p> <p>Results</p> <p>In univariate analysis, the e4 allele was negatively associated with low-GFR cases in non-Hispanic whites, odds ratio (OR): 0.76, 95% confidence interval (CI): 0.60, 0.97. In whites, there was a significant association between increasing <it>APOE </it>score (indicating greater number of e2 alleles) and higher prevalence of low-GFR cases (OR: 1.21, 95%CI: 1.01, 1.45). Analysis of continuous GFR in whites found the e4 allele was associated with higher levels of continuous GFR (β-coefficient: 2.57 ml/min/1.73 m<sup>2</sup>, 95%CI: 0.005, 5.14); in non-Hispanic blacks the e2 allele was associated with lower levels of continuous GFR (β-coefficient: -3.73 ml/min/1.73 m<sup>2</sup>, 95%CI: -6.61, -0.84). <it>APOE </it>e2 and e4 alleles were rare and not associated with low-GFR cases or continuous GFR in Mexican Americans.</p> <p>Conclusion</p> <p>In conclusion, the authors observed a weak association between the <it>APOE </it>e4 allele and low-GFR cases and continuous GFR in non-Hispanic whites, and the <it>APOE </it>e2 allele and continuous GFR in non-Hispanic blacks, but found no association with either measure of kidney function in Mexican Americans. Larger studies including multiethnic groups are needed to determine the significance of this association.</p
Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees
<p>Abstract</p> <p>Background</p> <p>Prior studies have found that patients taking single-pill amlodipine/atorvastatin (SPAA) have greater likelihood of adherence at 6 months than those taking 2-pill calcium-channel blocker and statin combinations (CCB/statin). This study examines whether this adherence benefit results in fewer cardiovascular (CV) events.</p> <p>Methods</p> <p>A retrospective cohort study was conducted using administrative claims data from the IMS LifeLink: US Health Plan Claims database, identifying adults already taking CCB or statin (but not both) who had an index event of either initiating treatment with SPAA or adding CCB to statin (or vice versa) between April 1, 2004 to August 31, 2005. Inclusion criteria included age 18+ years, continuously enrolled for minimum of 6 months prior and 18 months following treatment initiation, >1 diagnosis of hypertension, and no prescription claims for SPAA or added CCB or statin for 6 months prior. Exclusion criteria included >1 claim with missing or invalid days supplied, age 65+ years and not enrolled in Medicare Advantage, or history of prior CV events, cancer diagnosis, or chronic renal failure. The primary outcome measure was the rate of CV events (myocardial infarction, heart failure, angina, other ischemic heart disease, stroke, peripheral vascular disease, or revascularization procedure) from 6 to 18 months following index date, analyzed at three levels: 1) all adherent vs. non-adherent patients, 2) SPAA vs. dual-pill patients (regardless of adherence level), and 3) adherent SPAA, adherent dual-pill, and non-adherent SPAA patients vs. non-adherent dual-pill patients.</p> <p>Results</p> <p>Of 1,537 SPAA patients, 56.5% were adherent at 6 months, compared with 21.4% of the 17,910 CCB/statin patients (p < 0.001). Logistic regression found SPAA patients more likely to be adherent (OR = 4.7, p < 0.001) than CCB/statin patients. In Cox proportional hazards models, being adherent to either regimen was associated with significantly lower risk of CV event (HR = 0.77, p = 0.003). A similar effect was seen for SPAA vs. CCB/statin patients (HR = 0.68, p = 0.02). In a combined model, the risk of CV events was significantly lower for adherent CCB/statin patients (HR = 0.79, p = 0.01) and adherent SPAA patients (HR = 0.61, p = 0.03) compared to non-adherent CCB/statin patients.</p> <p>Conclusions</p> <p>Patients receiving SPAA rather than a 2-pill CCB/statin regimen are more likely to be adherent. In turn, adherence to CCB and statin medications is associated with lower risk of CV events in primary prevention patients.</p
Statins: another class of antihypertensive agents?
The assessment of global cardiovascular risk is an essential step in the
management of atherosclerotic disease prevention. Among the risk factors
to be addressed are hypertension and hyperlipidaemia; these commonly
coexist. A neutral or lipid-friendly antihypertensive agent is probably
useful in the presence of lipid abnormalities. Similarly, statins have
been shown to decrease cardiovascular risk in hypertensive patients.
There is also experimental and clinical evidence that statins have blood
pressure (BP)-lowering effects. In this review, we discuss the
beneficial effects of statins on BP, and provide an overview of the
underlying pathophysiology. We also consider the evidence justifying the
use of statins in the management of hypertensive patients
Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: Where we are now?
A large number of patients require antiplatelet therapy (mainly aspirin
and/or clopidogrel). Recent studies suggest that the combination of
these agents is useful in patients with acute coronary syndrome and
after percutaneous coronary intervention with stent placement. On the
other hand, bleeding complications, most of which arise from the upper
gastrointestinal (UGI) tract, can limit the use of antiplatelet drugs.
Clopidogrel appears to be associated with fewer UGI side effects and
bleeding compared with aspirin. However, a history of previous UGI
bleeding is a major risk factor for clopidogrel-associated bleeding. The
use of proton-pump inhibitors (PPIs) decreases the rate of UGI bleeding
in patients receiving aspirin or clopidogrel. Furthermore, a recent
study suggested that the administration of low-dose aspirin plus
high-dose esomeprazole (a potent PPI) was associated with fewer episodes
of UGI bleeding than clopidogrel alone in patients with a history of
recent UGI haemorrhage. However, this study had several limitations and
its results should be cautiously extrapolated into clinical practice.
The combination of aspirin plus clopidogrel increases the risk of UGI
bleeding. Unfortunately, there are no data on the effect of PPI
prophylaxis in this setting. Available evidence suggests that where
aspirin and/or clopidogrel are to be started or continued in patients
with a recent history of UGI ulceration or bleeding (after ulcer healing
and eradication of H. pylori infection), treatment with a PPI is a
useful precaution. The patients should also be carefully monitored for
recurrence of UGI bleeding
Reliability, availability and maintainability analysis in food production lines: a review
Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study
Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population
- …